Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018337 · ClinicalTrials.gov registry record · Phase 3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
A Phase 3 study of Metastatic Breast Cancer, sponsored by DualityBio.
- Active
- Registry status
- Phase 3
- Development phase
- 541
- Enrollment target
- 20
- Study locations
NCT06018337: Active Phase 3 study of Metastatic Breast Cancer, sponsored by DualityBio.
NCT06018337 is a Phase 3 study of Metastatic Breast Cancer that is active but no longer recruiting, run by DualityBio. The registered enrollment target is 541 participants, above the 201-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (169% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06018337, a Phase 3 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by DualityBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 541 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Primary Outcome
PFS by BICR according to RECIST 1.1 in the HR+, HER2-low population
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Nab-paclitaxel
- DRUG DB-1303/BNT323
Study Locations (20)
California
- Research Site 1114-0 - Fullerton
- Research Site 1107-0 - Los Angeles
- Research Site 1118-0 - Orange
- Research Site 1143-0 - Sacramento
- Research Site 1132-0 - Santa Barbara
Florida
- Research Site 1154-0 - Jacksonville
- Research Site 1145-0 - Miami
- Research Site 1150-0 - Orange City
- Research Site 1125-0 - Palm Bay
Colorado
- Research Site 1137-0 - Aurora
- Research Site 1129-0 - Lone Tree
Georgia
- Research Site 1155-0 - Athens
- Research Site 1110-0 - Savannah
Illinois
- Research Site 1147-0 - Chicago
- Research Site 1124-0 - Chicago Ridge
Arizona
- Research Site 1141-0 - Tucson
Indiana
- Research Site 1152-0 - Fort Wayne
Kansas
- Research Site 1106-0 - Merriam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 541 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What the registry record for NCT06018337 still lists
NCT06018337 is an interventional study that assigns participants to a tested intervention. The registered 541 participants enrollment target is mid-sized for trials with a published cap, above the 201-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (169% higher).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT06018337 names 20 study sites across 10 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06018337 about?
NCT06018337 is a clinical study titled "A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)". The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- an...
What is the current status of trial NCT06018337?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 541 participants. The study started on 2024-01-18. Estimated completion is 2028-07.
What conditions does trial NCT06018337 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT06018337?
The interventions under investigation include: Capecitabine (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG), DB-1303/BNT323 (DRUG).
Who is sponsoring clinical trial NCT06018337?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018337 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06018337's enrollment target sits among peer trials
541 7th of 139 higher than 133 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RECRUITING · Phase 3
-
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RECRUITING · Phase 3
-
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
-
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 3
-
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04929223 · 542 participants · Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- NCT05584670 · 542 participants · Phase 1
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI